BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $39.75 Average Target Price from Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has been given a consensus rating of “Hold” by the seven brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $39.75.

Several research firms have issued reports on BTAI. Zacks Research lowered BioXcel Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of BioXcel Therapeutics in a research report on Monday, September 15th.

BioXcel Therapeutics Trading Down 0.6%

BioXcel Therapeutics stock opened at $1.73 on Friday. BioXcel Therapeutics has a 12 month low of $1.17 and a 12 month high of $9.26. The company has a market capitalization of $37.84 million, a price-to-earnings ratio of -0.18 and a beta of 0.21. The business’s fifty day simple moving average is $2.00 and its two-hundred day simple moving average is $2.55.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.64). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts predict that BioXcel Therapeutics will post -24.39 EPS for the current year.

Institutional Investors Weigh In On BioXcel Therapeutics

Several large investors have recently made changes to their positions in the company. Diversify Wealth Management LLC bought a new stake in BioXcel Therapeutics during the 2nd quarter valued at $27,000. XTX Topco Ltd acquired a new stake in BioXcel Therapeutics in the second quarter worth about $42,000. Goldman Sachs Group Inc. acquired a new position in shares of BioXcel Therapeutics during the first quarter valued at about $50,000. Geode Capital Management LLC grew its position in BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares during the last quarter. Finally, Foundations Investment Advisors LLC purchased a new stake in shares of BioXcel Therapeutics during the third quarter valued at $76,000. 30.68% of the stock is owned by institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.